Eisai Co. Ltd (EII F) stock market data APIs

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals, and other business in Japan, America, China, Europe, Asia and internationally. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; Rozebalamin, for amyotrophic lateral sclerosis; URECE, treatment for gout and hyperuricemia; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. The company also engages in public-private partnerships to improve global access to medicines for infectious and tropical diseases. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.